结肠癌肝转移的转录组生物标志物对新辅助三重化疗的反应:一个案例系列
Nataliya Babyshkina1,2, Tatyana Dronova1, Dmitry Eremin1
1Department of Molecular Oncology and Immunology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk - Russian Federation.
Journal of circulating biomarkers
|November 13, 2025
概括
新辅助性FOLFOXIRI化疗在结肠瘤和肝转移中显示出明显的基因表达变化. 基因EPS8L2可能表明肝脏对这种转移性结肠癌治疗的完整反应.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 转移性结肠癌 (mCRC) 治疗受益于新辅助化疗.
- 福尔福克西里 (甲,莱可沃林,甲和伊利诺丁) 是一种潜在的mCRC新辅助疗法.
- 了解分子反应可以个性化治疗.
研究的目的:
- 在mCRC中识别治疗反应的分子标记.
- 为了比较新辅助药FOLFOXIRI后的原发性瘤和肝转移的转录形状.
主要方法:
- 来自五名mCRC患者的结合瘤和正常组织的RNA测序 (RNA-seq).
- 在新辅助药FOLFOXIRI之前和之后对初级结肠瘤和肝转移的分析.
主要成果:
- 肝转移显示出比原发性瘤更多的差异表达基因 (DEGs).
- 特定的基因 (例如IL1RN,ALDH1A1,FOS) 与结肠瘤反应有关.
- 其他基因 (例如HBB,DUSP1,SERPINE1) 可能参与肝转移反应.
- 在完全响应者的肝组织中,EPS8L2的表达很高.
结论:
- 在FOLFOXIRI后的原发性瘤和转移中,转录形状不同.
- 与治疗反应相关的基因表达模式是不同的.
- EPS8L2是mCRC中肝脏完整反应的潜在生物标志物.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


